StrokeNCT06804304
Efficacy of Music-Based Telerehabilitation After Stroke
A study testing Music-based telerehabilitation in people with Stroke, run by Teppo Sarkamo at 1 site in Finland.
Trial summary
The goal of this clinical trial is to learn if a music-based telerehabilitation intervention implemented at home works to treat different kinds of neurological deficits caused by stroke. Read more about this study
- Who is it for?
- Ages 30 to 80 years
- Conditions the study is for
- Stroke
- What is being tested?
- Music-based telerehabilitation
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteFinland
- Study dates
- 1 Feb 2025to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Left or right hemisphere stroke which has occurred at least 3 months ago
- At least mild cognitive deficit and mild aphasia / upper-extremity hemiparesis caused by the stroke
- Age 30-80 years
- Finnish-speaking (or bilingual, able to participate in Finnish)
- Understands the purpose of the study and is able to give informed consent
Who cannot join
- Prior significant hearing or visual impairment
- Prior severe psychiatric illness (e.g., schizopheria, bipolar disorder, severe unipolar depression)
- Prior severe neurological illness (e.g., brain injury, dementia; can have prior TIA or mild stroke)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Finland1 site, 1 recruiting
- Recruiting
University of Helsinki / Faculty of Medicine / Department of Psychology
Helsinki, 00014
Nella Moisseinen, M.A., +358504070507, nella.moisseinen@helsinki.fi
Teppo Särkämö, Ph.D., +358505399065, teppo.sarkamo@helsinki.fi
About this study
The goal of this clinical trial is to learn if a music-based telerehabilitation intervention implemented at home works to treat different kinds of neurological deficits caused by stroke. The main questions it aims to answer are: 1) Can the music intervention improve recovery of cognitive, verbal, motor, and emotional deficits after stroke, 2) can the music intervention enhance structural and functional recovery of the brain, and (3) how different demographic, musical, and clinical background factors affect the way the music intervention works. Researchers will compare the music intervention to standard (usual) care to see if the music intervention works to treat the deficits caused by stroke. Subjects are stroke patients who will participate either in the music intervention 5 times/week for 10 weeks in addition to standard care or receive standard care only. During the trial, the subjects will undergo neuropsychological testing and magnetic resonance imaging (MRI) three times: at baseline (before the intervention), at 3-month stage (immediately after the intervention), and at 6-month stage (3 months after the intervention).
- Conditions
- Stroke
- Being tested
- Music-based telerehabilitation
- Keywords
- stroke, music, telerehabilitation, attention, executive function, memory, cognition, language, aphasia, motor, hemiparesis, emotion, depression, anxiety, quality of life, magnetic resonance imaging, neuroplasticity
- Medical subject headings
- Stroke, Language, Aphasia, Paresis, Depression, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Music-based telerehabilitationBehavioural
The music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min).
| Study group | Role | What they receive |
|---|---|---|
| Music intervention plus standard care | Experimental | Participation in a music-based telerehabilitation program (10 weeks, 5 days/week, 60 min/day) in addition to standard care for post-stroke deficits provided in public health care (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation). Receives: Behavioral: Music-based telerehabilitation |
| Standard care only | No intervention | Standard care for post-stroke deficits provided in public health care (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation). No additional intervention is provided. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the cognitive functioning summary score from baseline to 3-month stage
Cognitive functioning summary score is calculated as an average of rescaled scores in following tests: Montreal Cognitive Assessment (MoCA) total score, MoCA Verbal Fluency subtest total score, Sustained Attention to Response Task (SART; correct responses \& reaction times), Flexible Attention Test (FAT) / Reaction Time subtest (reaction times) and Trail Making subtest (correct responses \& reaction times from difference scores between B part and A part), Simon Task (correct responses \& reaction times from difference scores between Incongruence part and Congruence part), and Wechsler Memory Scale III (WMS-III) / Digit Span subtest (total score) and Spatial Span subtest (total score). Raw scores are rescaled to a scale of 0-100 using min-max normalization [(x-min(x))/(max(x)-min(x))*100] across the measurement points. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 3-month stage
Change in the speech production summary score from baseline to 3-month stage
Speech production summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in the following subtests of the Western Aphasia Battery (WAB): Conversational Question, Picture Description, Repetition, Object Naming, Word Fluency, Sentence Completion, and Responsive Speech. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 3-month stage
Change in the upper-extremity motor function summary score from baseline to 3-month stage
Upper-extremity motor function summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in following tests: Action Research Arm Test (ARAT; total score), Box and Block Test (BBT; total score), and Purdue Pegboard Test (PPT; total score). The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 3-month stage
Change in the mood and quality of life summary score from baseline to 3-month stage
Mood and quality of life summary score is calculated as an average of percentage scores (score/maximum value*100; range 0-100) in following self-report questionnaires: Patient-Reported Outcomes Measurement Information System (PROMIS) / Depression scale (total score), PROMIS / Anxiety scale (total score), and Stroke Impact Scale (SIS; total score). The scores of the PROMIS are reversed to align with the SIS scores. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 3-month stage
Secondary outcomes (109)
Change in the cognitive functioning summary score from baseline to 6-month stage
Cognitive functioning summary score is calculated as an average of rescaled scores in following tests: Montreal Cognitive Assessment (MoCA) total score, MoCA Verbal Fluency subtest total score, Sustained Attention to Response Task (SART; correct responses \& reaction times), Flexible Attention Test (FAT) / Reaction Time subtest (reaction times) and Trail Making subtest (correct responses \& reaction times from difference scores between B part and A part), Simon Task (correct responses \& reaction times from difference scores between Incongruence part and Congruence part), and Wechsler Memory Scale III (WMS-III) / Digit Span subtest (total score) and Spatial Span subtest (total score). Raw scores are rescaled to a scale of 0-100 using min-max normalization [(x-min(x))/(max(x)-min(x))*100] across the measurement points. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 6-month stage
Change in the speech production summary score from baseline to 6-month stage
Speech production summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in the following subtests of the Western Aphasia Battery (WAB): Conversational Question, Picture Description, Repetition, Object Naming, Word Fluency, Sentence Completion, and Responsive Speech. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 6-month stage
Change in the upper-extremity motor function summary score from baseline to 6-month stage
Upper-extremity motor function summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in following tests: Action Research Arm Test (ARAT; total score), Box and Block Test (BBT; total score), and Purdue Pegboard Test (PPT; total score). The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 6-month stage
Change in the mood and quality of life summary score from baseline to 6-month stage
Mood and quality of life summary score is calculated as an average of percentage scores (score/maximum value*100; range 0-100) in following self-report questionnaires: Patient-Reported Outcomes Measurement Information System (PROMIS) / Depression scale (total score), PROMIS / Anxiety scale (total score), and Stroke Impact Scale (SIS; total score). The scores of the PROMIS are reversed to align with the SIS scores. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline and 6-month stage
Change in the attention summary score from baseline to 3-month and 6-month stages
Attention summary score is calculated as an average of rescaled scores in following tests: Sustained Attention to Response Task (SART; correct responses \& reaction times), Flexible Attention Test (FAT) / Reaction Time subtest (reaction times) and Trail Making subtest (correct responses \& reaction times from A part), and Simon Task (correct responses \& reaction times from Congruence part). Raw scores are rescaled to a scale of 0-100 using min-max normalization [(x-min(x))/(max(x)-min(x))*100] across the measurement points. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the executive function summary score from baseline to 3-month and 6-month stages
Executive function summary score is calculated as an average of rescaled scores in following tests: MoCA Verbal Fluency subtest total score, Flexible Attention Test (FAT) / Trail Making subtest (correct responses \& reaction times from difference scores between B part and A part), and Simon Task (correct responses \& reaction times from difference scores between Incongruence part and Congruence part). Raw scores are rescaled to a scale of 0-100 using min-max normalization [(x-min(x))/(max(x)-min(x))*100] across the measurement points. The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the working memory summary score from baseline to 3-month and 6-month stages
Working memory summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in the Wechsler Memory Scale III (WMS-III) / Digit Span subtest (total score) and Spatial Span subtest (total score). The range of the summary score is 0-100 (higher score indicates better outcome).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the MoCA total score from baseline to 3-month and 6-month stages
Montreal Cognitive Assessment (MoCA) total score (range 0-30, higher score indicates better outcome), measures general cognitive function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the MoCA Verbal Fluency subtest score from baseline to 3-month and 6-month stages
Montreal Cognitive Assessment (MoCA) Verbal Fluency subtest score (phonemic fluency; min value: 0, max value: no upper limit; higher score indicates better outcome), measures executive functioning (cognitive flexibility).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the SART correct responses from baseline to 3-month and 6-month stages
Sustained Attention to Response Task (SART), number of correct responses (range 0-225, higher score indicates better outcome), measures sustained attention.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the SART reaction times from baseline to 3-month and 6-month stages
Sustained Attention to Response Task (SART), average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures sustained attention.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Reaction Time subtest reaction times from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Reaction Time subtest, average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures selective attention \& psychomotor speed.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (A part) correct responses from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Trail Making subtest (A part), number of correct responses (range 0-24, higher score indicates better outcome), measures selective attention.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (A part) reaction times from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Trail Making subtest (A part), average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures selective attention.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (B part) correct responses from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Trail Making subtest (B part), number of correct responses (range 0-24, higher score indicates better outcome), measures executive function (set-shifting).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (B part) reaction times from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Trail Making subtest (B part), average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures executive function (set-shifting).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (difference between B part and A part) correct responses from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Trail Making subtest (difference between B part and A part), number of correct responses (range 0-24, lower score indicates better outcome), measures executive function (set-shifting).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (difference between B part and A part) reaction times from baseline to 3-month and 6-month stages
Flexible Attention Test (FAT) / Trail Making subtest (difference between B part and A part), average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures executive function (set-shifting).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Congruence part) correct responses from baseline to 3-month and 6-month stages
Simon Task / Congruence part, number of correct responses (range 0-50, higher score indicates better outcome), measures selective attention.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Congruence part) reaction times from baseline to 3-month and 6-month stages
Simon Task / Congruence part, average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures selective attention.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Incongruence part) correct responses from baseline to 3-month and 6-month stages
Simon Task / Incongruence part, number of correct responses (range 0-50, higher score indicates better outcome), measures executive function (inhibition).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Incongruence part) reaction times from baseline to 3-month and 6-month stages
Simon Task / Incongruence part, average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures executive function (inhibition).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (difference between Incongruence part and Congruence part) correct responses from baseline to 3-month and 6-month stages
Simon Task: Difference between Incongruence part and Congruence part, number of correct responses (range 0-50, lower score indicates better outcome), measures executive function (set-shifting).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (difference between Incongruence part and Congruence part) reaction times from baseline to 3-month and 6-month stages
Simon Task: Difference between Incongruence part and Congruence part, average reaction time (ms) across trials (scores do not have a fixed range, lower score indicates better outcome), measures executive function (set-shifting).
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Digit Span subtest (forward recall score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Digit Span subtest, forward recall score (range 0-16, higher score indicates better outcome), measures verbal working memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Digit Span subtest (backward recall score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Digit Span subtest, backward recall score (range 0-14, higher score indicates better outcome), measures verbal working memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Digit Span subtest (total score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Digit Span subtest, total score (range 0-30, higher score indicates better outcome), measures verbal working memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Spatial Span subtest (forward recall score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Spatial Span subtest, forward recall score (range 0-16, higher score indicates better outcome), measures visuospatial working memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Spatial Span subtest (backward recall score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Spatial Span subtest, backward recall score (range 0-16, higher score indicates better outcome), measures visuospatial working memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Spatial Span subtest (total score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Spatial Span subtest, total score (range 0-32, higher score indicates better outcome), measures visuospatial working memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (1st learning trial score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Word Lists subtest, 1st learning trial score (range 0-12, higher score indicates better outcome), measures verbal memory \& learning
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (learning trials change score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Word Lists subtest, change score from the 1st to 4th learning trial (range 0-12, higher score indicates better outcome), measures verbal memory \& learning.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (learning trials total score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Word Lists subtest, total score over 4 learning trials (range 0-48, higher score indicates better outcome), measures verbal memory \& learning.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (learning trials recognition score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Word Lists subtest, recognition (old-new) score after 4 learning trials (range 0-24, higher score indicates better outcome), measures verbal memory \& learning.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (delayed recall score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Word Lists subtest, delayed recall score (range 0-12, higher score indicates better outcome), measures verbal memory \& learning.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (delayed recognition score) from baseline to 3-month and 6-month stages
Wechsler Memory Scale III (WMS-III) / Word Lists subtest, recognition (old-new) score after delay (range 0-24, higher score indicates better outcome), measures verbal memory \& learning.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (immediate recall score) from baseline to 3-month and 6-month stages
Rivermead Behavioural Memory Test (RBMT) / Story Recall subtest, immediate recall score (range 0-42, higher score indicates better outcome), measures episodic memory
Measured: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (immediate recognition score) from baseline to 3-month and 6-month stages
Rivermead Behavioural Memory Test (RBMT) / Story Recall subtest, recognition (old-new) score after immediate recall (range 0-12, higher score indicates better outcome), measures episodic memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (delayed recall score) from baseline to 3-month and 6-month stages
Rivermead Behavioural Memory Test (RBMT) / Story Recall subtest, delayed recall score (range 0-42, higher score indicates better outcome), measures episodic memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (delayed recognition score) from baseline to 3-month and 6-month stages
Rivermead Behavioural Memory Test (RBMT) / Story Recall subtest, recognition (old-new) score after delay (range 0-12, higher score indicates better outcome), measures episodic memory.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BIT Star Cancellation subtest (left side score) from baseline to 3-month and 6-month stages
Behavioral Inattention Test (BIT) / Star Cancellation subtest, number of correctly marked items on the left side (range 0-27, higher score indicates better outcome), measures spatial attention (unilateral spatial neglect)
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BIT Star Cancellation subtest (right side score) from baseline to 3-month and 6-month stages
Behavioral Inattention Test (BIT) / Star Cancellation subtest, number of correctly marked items on the right side (range 0-27, higher score indicates better outcome), measures spatial attention (unilateral spatial neglect)
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BIT Star Cancellation subtest (laterality index) from baseline to 3-month and 6-month stages
Behavioral Inattention Test (BIT) / Star Cancellation subtest, ratio of correctly marked items on the left side to total correctly marked items (range 0-1, lower score indicates better outcome), measures spatial attention (unilateral spatial neglect)
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BIT Star Cancellation subtest (total score) from baseline to 3-month and 6-month stages
Behavioral Inattention Test (BIT) / Star Cancellation subtest, number of correctly marked items (range 0-54, higher score indicates better outcome), measures spatial attention (unilateral spatial neglect)
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Conversational Question subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Conversational Question subtest, score (range 0-6, higher score indicates better outcome), measures spontaneous speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Conversational Question & Picture Description subtests (information content score) from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Conversational Question \& Picture Description subtests, information content score (range 0-10, higher score indicates better outcome), measures spontaneous speech production
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Conversational Question & Picture Description subtests (fluency of speech score) from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Conversational Question \& Picture Description subtests, fluency of speech score (range 0-10, higher score indicates better outcome), measures spontaneous speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Spontaneous speech score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Spontaneous speech score (sum of information content and fluency of speech scores; range 0-20, higher score indicates better outcome), measures spontaneous speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Conversational Question & Picture Description subtests (efficiency score) from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Conversational Question \& Picture Description subtests, number of correct information units per minute (min: 0, max: no fixed value, higher score indicates better outcome), measures spontaneous speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Repetition subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Repetition subtest, score (range: 0-100, higher score indicates better outcome), measures responsive speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Object Naming subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Object Naming subtest, score (range: 0-60, higher score indicates better outcome), measures responsive speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Word Fluency subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Word Fluency subtest, score (range: 0-20, higher score indicates better outcome), measures responsive speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Sentence Completion subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Sentence Completion subtest, score (range: 0-10, higher score indicates better outcome), measures responsive speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Responsive Speech subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Responsive Speech subtest, score (range: 0-10, higher score indicates better outcome), measures responsive speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Naming and Word Finding score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Naming and Word Finding score (sum of Object Naming, Word Fluency, Sentence Completion, Responsive Speech subtest scores; range: 0-100, higher score indicates better outcome), measures responsive speech production.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the WAB Sequential Commands subtest score from baseline to 3-month and 6-month stages
Western Aphasia Battery (WAB) / Sequential Commands subtest, score (range: 0-80, higher score indicates better outcome), measures verbal comprehension.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BDAE Verbal Agility subtest score from baseline to 3-month and 6-month stages
Boston Diagnostic Aphasia Examination (BDAE) / Verbal Agility subtest, score (range: 0-14, higher score indicates better outcome), measures motor production of speech
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BDAE Automatized Sequences subtest score from baseline to 3-month and 6-month stages
Boston Diagnostic Aphasia Examination (BDAE) / Automatized Sequences subtest, score (range: 0-8, higher score indicates better outcome), measures non-propositional speech.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Grasp subscale score (paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Grasp subscale score of the paretic hand (range: 0-18, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Grasp subscale score (non-paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Grasp subscale score of the non-paretic hand (range: 0-18, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Grip subscale score (paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Grip subscale score of the paretic hand (range: 0-12, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Grip subscale score (non-paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Grip subscale score of the non-paretic hand (range: 0-12, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Pinch subscale score (paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Pinch subscale score of the paretic hand (range: 0-18, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Pinch subscale score (non-paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Pinch subscale score of the non-paretic hand (range: 0-18, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Gross Movement subscale score (paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Gross Movement subscale score of the paretic hand (range: 0-9, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT Gross Movement subscale score (non-paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) / Gross Movement subscale score of the non-paretic hand (range: 0-9, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT total score (paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) total score of the paretic hand (range: 0-57, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT total score (non-paretic hand) from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) total score of the non-paretic hand (range: 0-57, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the ARAT total score from baseline to 3-month and 6-month stages
Action Research Arm Test (ARAT) total score (both paretic \& non-paretic hands; range: 0-114, higher score indicates better outcome), measures upper-extremity motor function.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BBT paretic hand score from baseline to 3-month and 6-month stages
Box and Block Test (BBT) total score for the paretic hand (range: 0-150, higher score indicates better outcome), measures gross manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BBT non-paretic hand score from baseline to 3-month and 6-month stages
Box and Block Test (BBT) total score for the non-paretic hand (range: 0-150, higher score indicates better outcome), measures gross manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the BBT total score from baseline to 3-month and 6-month stages
Box and Block Test (BBT) total score for both hands (range: 0-300, higher score indicates better outcome), measures gross manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the PPT paretic hand score from baseline to 3-month and 6-month stages
Purdue Pegboard Test (PPT) score of the paretic hand (range: 0-25, higher score indicates better outcome), measures fine manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the PPT non-paretic hand score from baseline to 3-month and 6-month stages
Purdue Pegboard Test (PPT) score of the non-paretic hand (range: 0-25, higher score indicates better outcome), measures fine manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the PPT both hands score from baseline to 3-month and 6-month stages
Purdue Pegboard Test (PPT) score of both hands (range: 0-25, higher score indicates better outcome), measures fine manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the PPT total score from baseline to 3-month and 6-month stages
Purdue Pegboard Test (PPT) total score (range: 0-75, higher score indicates better outcome), measures fine manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in the PPT Assembly score from baseline to 3-month and 6-month stages
Purdue Pegboard Test (PPT) Assembly score (range: 0-80, higher score indicates better outcome), measures fine manual dexterity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in PROMIS Depression subscale total score from baseline to 3-month and 6-month stages
Patient-Reported Outcomes Measurement Information System (PROMIS) / Depression subscale total score (patient self-report; range: 5-40, lower score indicates better outcome), measures depression.
Measured: Baseline, 3-month stage, and 6-month stage
Change in PROMIS Anxiety subscale total score from baseline to 3-month and 6-month stages
Patient-Reported Outcomes Measurement Information System (PROMIS) / Anxiety subscale total score (patient self-report; range: 5-40, lower score indicates better outcome), measures anxiety.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Strength subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Strength subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures strength of the paretic upper-extremity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Hand Function subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Hand Function subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures hand function of the paretic upper-extremity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS ADL subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / ADL subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures ability to perform activities of daily living.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Mobility subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Mobility subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures mobility in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Communication subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Communication subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures communication ability in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Emotion subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Emotion subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures mood.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Memory and Thinking subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Memory and Thinking subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures cognitive functioning in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Participation subscale score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Participation subscale score (patient self-report; range: 0-100, higher score indicates better outcome), measures social interaction and involvement in life situations.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Recovery item score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Recovery item score (patient self-report using visual analogue scale, range: 0-100, higher score indicates better outcome), measures patient's perception of their overall recovery from stroke.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS total score (patient self-report) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) total score (patient self-report; range: 0-900, higher score indicates better outcome), measures overall quality of life after stroke.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Strength subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Strength subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures strength of the paretic upper-extremity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Hand Function subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Hand Function subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures hand function of the paretic upper-extremity.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS ADL subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / ADL subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures ability to perform activities of daily living.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Mobility subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Mobility subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures mobility in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Communication subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Communication subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures communication ability in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Emotion subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Emotion subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures mood.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Memory and Thinking subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Memory and Thinking subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures cognitive functioning in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Participation subscale score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Participation subscale score (proxy report of family member; range: 0-100, higher score indicates better outcome), measures social interaction and involvement in life situations.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS Recovery item score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) / Recovery item score (proxy report of family member using visual analogue scale, range: 0-100, higher score indicates better outcome), measures family member's perception of patient's overall recovery from stroke.
Measured: Baseline, 3-month stage, and 6-month stage
Change in SIS total score (proxy report of family member) from baseline to 3-month and 6-month stages
Stroke Impact Scale (SIS) total score (proxy report of family member; range: 0-900, higher score indicates better outcome), measures overall quality of life after stroke.
Measured: Baseline, 3-month stage, and 6-month stage
Change in MAL total score (patient self-report) from baseline to 3-month and 6-month stages
Motor Activity Log (MAL) total score (patient self-report; range: 0-70, higher score indicates better outcome), measures severity of upper-extremity paresis.
Measured: Baseline, 3-month stage, and 6-month stage
Change in MAL total score (proxy report of family member) from baseline to 3-month and 6-month stages
Motor Activity Log (MAL) total score (proxy report of family member; range: 0-70, higher score indicates better outcome), measures severity of upper-extremity paresis.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CAL Quantity of Communication scale score (patient self-report) from baseline to 3-month and 6-month stages
Communicative Activity Log (CAL) / Quantity of Communication score (patient self-report; range: 0-90, higher score indicates better outcome), measures quantity of communication in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CAL Quality of Communication score (patient self-report) from baseline to 3-month and 6-month stages
Communicative Activity Log (CAL) / Quality of Communication scale score (patient self-report; range: 0-90, higher score indicates better outcome), measures quality of communication in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CAL total score (patient self-report) from baseline to 3-month and 6-month stages
Communicative Activity Log (CAL) total score (patient self-report; range: 0-180, higher score indicates better outcome), measures communication ability in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CAL Quantity of Communication scale score (proxy report of family member) from baseline to 3-month and 6-month stages
Communicative Activity Log (CAL) / Quantity of Communication score (proxy report of family member; range: 0-90, higher score indicates better outcome), measures quantity of communication in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CAL Quality of Communication score (proxy report of family member) from baseline to 3-month and 6-month stages
Communicative Activity Log (CAL) / Quality of Communication scale score (proxy report of family member; range: 0-90, higher score indicates better outcome), measures quality of communication in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CAL total score (proxy report of family member) from baseline to 3-month and 6-month stages
Communicative Activity Log (CAL) total score (proxy report of family member; range: 0-180, higher score indicates better outcome), measures communication ability in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in CFQ total score (patient self-report) from baseline to 3-month and 6-month stages
Cognitive Failures Questionnaire (CFQ) total score (patient self-report; range: 0-100, lower score indicates better outcome), measures severity of attention and executive deficits in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Change in PRMQ total score (patient self-report) from baseline to 3-month and 6-month stages
Prospective and Retrospective Memory Questionnaire (PRMQ) total score (patient self-report; range: 5-80, higher score indicates better outcome), measures memory functioning in daily life.
Measured: Baseline, 3-month stage, and 6-month stage
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2025
- Study start1 Feb 2025
- Primary completionJun 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Teppo Sarkamo
- Sponsor type
- University, hospital or other
- Collaborators
- HUS Neurocenter, HUS Medical Imaging Centre, University of Jyvaskyla, Finnish Brain Association, Uusimaa Stroke Association
- Responsible party
- Sponsor-investigator, Teppo Sarkamo, University of Helsinki
- Investigators
- Teppo Särkämö, Ph.D., Principal investigator, University of Helsinki / Faculty of Medicine / Department of Psychology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06804304
- Sponsor's protocol ID
- HUS/5459/2024
- Status last verified
- Apr 2026
- First submitted
- 23 Jan 2025
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Laakso E, Oksanen E, Kaila LM, Salakka I, Kauramaki J, Lahdenpera N, Pitkaniemi A, Sihvonen AJ, Moisseinen N, Sarkamo T. Efficacy of music-based telerehabilitation after stroke: protocol description of a randomised controlled trial. BMJ Open. 2026 Sep 24;16(9):e124110. doi: 10.1136/bmjopen-2026-124110.
PubMed 42785935
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Music-Based Telerehabilitation After Stroke
- ClinicalTrials.gov ID
- NCT06804304
- Acronym / sponsor ID
- HUS/5459/2024
- Conditions
- Stroke
- Keywords
- stroke, music, telerehabilitation, attention, executive function, memory, cognition, language
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Teppo SarkamoUniversity, hospital or other
- Collaborators
- HUS Neurocenter, HUS Medical Imaging Centre, University of Jyvaskyla, Finnish Brain Association, Uusimaa Stroke Association
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 3 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a music-based telerehabilitation intervention implemented at home works to treat different kinds of neurological deficits caused by stroke. The main questions it aims to answer are: 1) Can the music intervention improve recovery of cognitive, verbal, motor, and emotional deficits after stroke, 2) can the music intervention enhance structural and functional recovery of the brain, and (3) how different demographic, musical, and clinical background factors affect the way the music intervention works. Researchers will compare the music intervention to standard (usual) care to see if the music intervention works to treat the deficits caused by stroke. Subjects are stroke patients who will participate either in the music intervention 5 times/week for 10 weeks in addition to standard care or receive standard care only. During the trial, the subjects will undergo neuropsychological testing and magnetic resonance imaging (MRI) three times: at baseline (before the intervention), at 3-month stage (immediately after the intervention), and at 6-month stage (3 months after the intervention).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Music intervention plus standard care | Experimental | Behavioral: Music-based telerehabilitationParticipation in a music-based telerehabilitation program (10 weeks, 5 days/week, 60 min/day) in addition to standard care for post-stroke deficits provided in public health care (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation). |
| Standard care only | No intervention | –Standard care for post-stroke deficits provided in public health care (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation). No additional intervention is provided. |
Who may qualify
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Left or right hemisphere stroke which has occurred at least 3 months ago
- At least mild cognitive deficit and mild aphasia / upper-extremity hemiparesis caused by the stroke
- Age 30-80 years
- Finnish-speaking (or bilingual, able to participate in Finnish)
- Understands the purpose of the study and is able to give informed consent
Key exclusion criteria (3 listed)
- Prior significant hearing or visual impairment
- Prior severe psychiatric illness (e.g., schizopheria, bipolar disorder, severe unipolar depression)
- Prior severe neurological illness (e.g., brain injury, dementia; can have prior TIA or mild stroke)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Music-based telerehabilitationThe music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min). | Behavioural | Music intervention plus standard care |
Primary outcome
Change in the cognitive functioning summary score from baseline to 3-month stage
Time frame: Baseline and 3-month stage
Cognitive functioning summary score is calculated as an average of rescaled scores in following tests: Montreal Cognitive Assessment (MoCA) total score, MoCA Verbal Fluency subtest total score, Sustained Attention to Response Task (SART; correct responses \& reaction times), Flexible Attention Test (FAT) / Reaction Time subtest (reaction times) and Trail Making subtest (correct responses \& reaction times from difference scores between B part and A part), Simon Task (correct responses \& reaction times from difference scores between Incongruence part and Congruence part), and Wechsler Memory Scale III (WMS-III) / Digit Span subtest (total score) and Spatial Span subtest (total score). Raw scores are rescaled to a scale of 0-100 using min-max normalization [(x-min(x))/(max(x)-min(x))*100] across the measurement points. The range of the summary score is 0-100 (higher score indicates better outcome).
Change in the speech production summary score from baseline to 3-month stage
Time frame: Baseline and 3-month stage
Speech production summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in the following subtests of the Western Aphasia Battery (WAB): Conversational Question, Picture Description, Repetition, Object Naming, Word Fluency, Sentence Completion, and Responsive Speech. The range of the summary score is 0-100 (higher score indicates better outcome).
Change in the upper-extremity motor function summary score from baseline to 3-month stage
Time frame: Baseline and 3-month stage
Upper-extremity motor function summary score is calculated as an average of percentage of correct responses (score/maximum value*100; range 0-100) in following tests: Action Research Arm Test (ARAT; total score), Box and Block Test (BBT; total score), and Purdue Pegboard Test (PPT; total score). The range of the summary score is 0-100 (higher score indicates better outcome).
Change in the mood and quality of life summary score from baseline to 3-month stage
Time frame: Baseline and 3-month stage
Mood and quality of life summary score is calculated as an average of percentage scores (score/maximum value*100; range 0-100) in following self-report questionnaires: Patient-Reported Outcomes Measurement Information System (PROMIS) / Depression scale (total score), PROMIS / Anxiety scale (total score), and Stroke Impact Scale (SIS; total score). The scores of the PROMIS are reversed to align with the SIS scores. The range of the summary score is 0-100 (higher score indicates better outcome).
109 secondary outcomes
Change in the cognitive functioning summary score from baseline to 6-month stage
Time frame: Baseline and 6-month stage
Change in the speech production summary score from baseline to 6-month stage
Time frame: Baseline and 6-month stage
Change in the upper-extremity motor function summary score from baseline to 6-month stage
Time frame: Baseline and 6-month stage
Change in the mood and quality of life summary score from baseline to 6-month stage
Time frame: Baseline and 6-month stage
Change in the attention summary score from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the executive function summary score from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the working memory summary score from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the MoCA total score from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the MoCA Verbal Fluency subtest score from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the SART correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the SART reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Reaction Time subtest reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (A part) correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (A part) reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (B part) correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (B part) reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (difference between B part and A part) correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the FAT Trail Making subtest (difference between B part and A part) reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Congruence part) correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Congruence part) reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Incongruence part) correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (Incongruence part) reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (difference between Incongruence part and Congruence part) correct responses from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the Simon Task (difference between Incongruence part and Congruence part) reaction times from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Digit Span subtest (forward recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Digit Span subtest (backward recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Digit Span subtest (total score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Spatial Span subtest (forward recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Spatial Span subtest (backward recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Spatial Span subtest (total score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (1st learning trial score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (learning trials change score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (learning trials total score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (learning trials recognition score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (delayed recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the WMS-III Word Lists subtest (delayed recognition score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (immediate recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (immediate recognition score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (delayed recall score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Change in the RBMT Story Recall subtest (delayed recognition score) from baseline to 3-month and 6-month stages
Time frame: Baseline, 3-month stage, and 6-month stage
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Derived from this study: PubMed 42785935Laakso E, Oksanen E, Kaila LM, Salakka I, Kauramaki J, Lahdenpera N, Pitkaniemi A, Sihvonen AJ, Moisseinen N, Sarkamo T. Efficacy of music-based telerehabilitation after stroke: protocol description of a randomised controlled trial. BMJ Open. 2026 Sep 24;16(9):e124110. doi: 10.1136/bmjopen-2026-124110.
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Teppo Särkämö, Ph.D. principal investigator
University of Helsinki / Faculty of Medicine / Department of Psychology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Music-based telerehabilitation in people with Stroke, run by Teppo Sarkamo at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Teppo Särkämö, Ph.D. (+358505399065, teppo.sarkamo@helsinki.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the cognitive functioning summary score from baseline to 3-month stage (time frame: Baseline and 3-month stage). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06804304, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.